Professor Kevin Moore
Professor Of Hepatology
MB BS FRCP BSC PH.D
As a hepatolologist, Professor Moore sees patients with a wide range of liver diseases. He has a strong background in all aspects of general hepatology including alcohol misuse disorders, fatty liver disease as well as experience of looking after liver transplant patients.
Professor Moore trained at King’s College London. He has a BSc and PhD in biochemistry. He is in on the Specialist register for gastroenterology but only sees patients with Liver Disorders. He was initially appointed as an MRC Senior Clinical Fellow, before becoming Professor of Hepatology. He worked on the liver transplant rota for 20 years, caring for patients before and after liver transplantation. He now leads the Alcohol Care Team at the Royal Free Foundation NHS Trust, as well as seeing patients with undiagnosed liver disease.
He is also on the specialist register for Clinical Pharmacology and Therapeutics, as well as General Internal Medicine. As a general physician he is happy to see patients from any speciality to review or discuss their medication, or to see patients with unusual drug metabolism or side effects.
Royal Free Hospital, Hampstead
Hadley Wood Hospital, Barnet
- Alcoholic liver disease and alcohol misuse.
- Liver Screening
- Fatty liver disease
- Abnormal liver function tests
- Complications of cirrhosis
- Hepatorenal syndrome (acute kidney injury in cirrhosis)
- Acute on chronic liver failure
- Vascular function and complications of cirrhosis
- Hepatorenal syndrome
- Alcohol and health
- Liver conditions seen and managed:
- Cirrhosis and its complications (including ascites, hepatorenal syndrome, and hepatic encephalopathy)
- Alcohol related liver disease
- Fatty liver disease
- Chronic viral hepatitis including hepatitis C
- Autoimmune liver disease
- Any undiagnosed liver diseaseLiver transplant patients
The Oxford Handbook of Acute Medicine. Ramrakha P. & Moore K.P. 1997
The Oxford Handbook of Acute Medicine. Ramrakha P. & Moore K.P. 2004
The Oxford Handbook of Acute Medicine. Ramrakha P., Moore K.P. & Sam A. 2010
This ~870 page handbook is part of a popular handbook series in Medicine. It covers all aspects of Acute Medicine. It has been highly successful and has sold over 100 000 copies.
Peer Reviewed Publications
Ede R,Moore K.P., Marshall WJ and Williams R. Frequency of acute pancreatitis in fulminant hepatic failure using isoenzyme markers. Gut 1988; 29: 778-781.
Maltby N, Taylor GW, Ritter J, Moore K.P., Fuller R and Dollery CT. Leukotriene C4 elimination and metabolism in man. Journal of Allergy and Clinical Immunology 1990; 85: 3-9.
Panos M, Moore K.P., Vlavianos P, Chambers J, Anderson J, Gimson AES, Slater JDH, Rees LH, Westaby D and Williams R. Single total paracentesis for tense ascites: Sequential hemodynamic changes and right atrial size. Hepatology 1990; 11: 662-667.
Moore K.P., Taylor G, Maltby N, Siegers D, Fuller R, Dollery CT, and Williams R. Increased production of cysteinyl-leukotrienes in hepatorenal syndrome. Journal of Hepatology 1990; 11: 263-271.
Moore K.P., Ward P, Taylor G.W., and Williams R. Renal and extra-renal production of prostacyclin and thromboxane in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100: 1069-1077.
Moore K.P., J Wendon, M Frazer, J Karani, R Williams, and K.F Badr. Plasma Immunoreactive endothelin in hepatorenal syndrome and liver disease. New England Journal of Medicine 1992: 327: 1774-1779.
J Wharton, L Gordon, J Byrne, H Herzog, L Selbie, Moore K.P., M Sullivan, M Elder, G Moscoso, K Taylor, J Shine, and J Polak. Expression of the human neuropeptide tyrosine (NPY) Y1 receptor. Proceedings of the National Academy of Sciences 1993: 90: 687-691.
Morrow JD., Moore K.P., Awad J., Badr KF., Williams R. Roberts LJ. Marked overproduction of non-cyclooxygenase derived F2-isoprostanes in the hepatorenal syndrome. Journal of Lipid Mediators; 1993: 6:417-20.
Roberts L.J, Moore K.P., Zackert W, and Morrow J. D. Identification of the major urinary metabolite of the F2-isoprostane 8-isoprostaglandin F2a in humans. Journal of Biological Chemistry 1996: 271; 34: 20617-20620
Fernando B., R. Marley, S. Holt, R. Anand, D. Harry, P. Sanderson, R. Smith, G. Hamilton, and K. P. Moore. N-Acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 1998: 28: 689-94.
Moore K.P, Holt S.G., Patel R.P Svistunenko D.A, Zackert W., Goodier D., Reeder B., Clozel M, Anand R., Cooper C.E., Morrow J.D., Wilson M.., Darley-Usmar V., and L.J. Roberts II. A causative role for redox cycling of myoglobin and its inhibition by alkalinization in the pathogenesis and treatment of rhabdomyolysis induced renal failure. Journal of Biological Chemistry 1998: 273: 31731-31737.
Holt, D. Goodier., Marley R., Patch D., Burroughs A., Fernando B., Harry D & Moore K.P., N-Acetycytseine improves renal function in the hepatorenal syndrome. Lancet 1999: 353: 294-295.
S.G.Holt, Goodier D, Reeder B, Harvey S., Morrow J.D., Wilson M.T., Roberts L.J and Moore K.P. Increased lipid peroxidation in Rhabdomyolysis. Lancet 1999: 353: 1471.
Harry D., Anand R., Holt S., Marley R., Goodier D., and Moore K.P. Increased sensitivity to endotoxemia in cirrhosis. Hepatology 1999: 30:1198-1205.
Marley, M. Feelisch, S. Holt and Moore K.P A chemiluminescense based assay for S-nitrosoalbumin and other plasma S-nitrosothiols..
Free Radical Research 2000: 32: 1-9.
Turvill JL, Burroughs AK, & Moore K.P. Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet 2000:355: 2048-9.
Baldus S., Eiserich J.P., Mani A., Castro L., Figueroa M., Chumley P., Ma W., Tousson A. White R., Moore K.P., & Freeman B.A. Endothelial Transcytosis of Myeloperoxidase Confers Specificity to Vascular Extracellular Matrix Proteins as Targets of Tyrosine Nitration. Journal of Clinical Investigation 2001:108:1759-1770.
Rechner A. Kuhnle G, Bremner P., Hubbard G., Moore K.P., & C. Rice-Evans. The metabolic fate of dietary polyphenols in humans.. Free Radical Biology and Medicine 2002; 33 (2) 220-235.
Richardson G., Hicks S.L., Frost M.T., Moore K.P., Benjamin N., and G.M. McKnight. The ingestion of inorganic nitrate increases gastric S-nitrosothiol levels and inhibits platelet function in humans. Nitric Oxide 2002: 7: 24-29.
AR Rechner, G Kuhnle, H Hu, A Roedig-Penman, M van den Braak, Moore K.P.,Rice-Evans C. The metabolism of dietary polyphenols and the relevance to circulating levels of conjugated metabolites. Free Radical Research 2002 ;36:1229-41.
Crane M.S., Ollosson R., Moore K.P., Rossi A.R. & Megson I.L. Anti-platelet activity of nitric oxide is substantially prolonged through formation of plasma S-nitrosothiols: impact of low molecular weight thiols. Journal of Biological Chemistry 2002;277:46858-63
Fessel J.P, Porter N.A, Moore K.P., Sheller J.R., and L.J. Roberts. Discovery of new products of lipid peroxidation formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are up-regulated by increased oxygen tension. Proceedings of the National Academy of Sciences (USA) 2002;99:16713-8.
A.S. Pannala, A.R. Mani, J. P. E. Spencer, V. Skinner, K. R. Bruckdorfer, K. P. Moore and C.A. Rice-Evans. The effect of dietary nitrate on salivary, plasma and urinary nitrate metabolism in humans. Free Radical Biology and Medicine 2003; 1;34:576-84.
Mani AR, Pannala AS, Orie NN, Ollosson R, Harry D, Rice-Evans CA, Moore KP. Nitration of endogenous para-hydroxyphenylacetic acid and the metabolism of nitrotyrosine. Biochemical Journal. 2003;374:521-7.
Rechner AR, Smith MA, Kuhnle G, Gibson GR, Debnam ES, Srai SK, Moore KP, Rice-Evans CA. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radical Biology and Medicine. 2004;36:212-25.
Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Mani AR, Moore K, Miller GJ, Humphries SE, Hurel SJ, Montgomery HE Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. European Heart Journal. 2004;25:468-75
Martin HM, Moore KP, Bosmans E, Davies S, Burroughs AK, Dhillon AP, Tosh D, Harrison R Xanthine oxidoreductase is present in bile ducts of normal and cirrhotic liver. Free Radical Biology and Medicine. 2004;37:1214-23
Ebrahimkhani MR, Mani AR, Moore K.P Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis. Gut. 2005 54:1668-7.
Mani AR, Ebrahimkhani MR, Ippolito S, Ollosson R, Moore KP. Metalloprotein-dependent decomposition of S-nitrosothiols: studies on the stabilization and measurement of S-nitrosothiols in tissues. Free Radical Biology and Medicine. 2006; 40:1654-63.
Pannala AS, Mani AR, Rice-Evans CA, Moore KP. pH-dependent nitration of para-hydroxyphenylacetic acid in the stomach. Free Radical Biology and Medicine. 2006; 41:896-901.
Mani AR, Ippolito S, Moreno JC, Visser TJ, Moore KP. The metabolism and dechlorination of chlorotyrosine in vivo. Journal of Biological Chemistry; 2007;282:29114-21.
kuhnle GG, Story GW, Reda T, Mani AR, Moore KP, Lunn JC, Bingham SA. Diet-induced endogenous formation of nitroso compounds in the GI tract. Free Radical Biology and Medicine. 2007;43; 1040-7.
Wong F, Moore K, Dingemanse J, Jalan R. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome. Hepatology. 2008;47(1):160-8.
Stadlbauer V, Wright GA, Banaji M, Mukhopadhya A, Mookerjee RP, Moore K, Jalan R. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology. 2008;134:111-9.
Mani AR, Montagnese S, Jackson CD, Jenkins CW, Head IM, Stephens RC, Moore KP, Morgan MY. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. Am J Physiol Gastrointest Liver Physiol.2009;296:G330-8.
Kumar S, Hall RJ, Mani AR, Moore KP, Camici PG, Rimoldi OE, Williams AJ, Macleod KT.
Myocardial stunning is associated with impaired calcium uptake by sarcoplasmic reticulum.Biochemical Biophysical Research Communications. 2009; 387:77-82.
Charunwatthana P, Abul Faiz M, Ruangveerayut R, Maude RJ, Rahman MR, Roberts LJ 2nd,
Moore K, Bin Yunus E, Hoque MG, Hasan MU, Lee SJ, Pukrittayakamee S, Newton PN, White NJ, Day NP, Dondorp AM. N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. Crit Care Med. 2009;37(2):516-22
Boutaud O, Moore KP, Reeder BJ, Harry D, Howie AJ, Wang S, Carney CK, Masterson TS, Amin T, Wright DW, Wilson MT, Oates JA, Roberts LJ Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proceedings of the National Academy of Sciences 2010; 107:2699-704.
Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, Mann GE, Moore K, Roberts LJ 2nd, Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med. 2012;52(1):1-6.
Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Shah N, Mohamed FE, Jover-Cobos M, Macnaughtan J, Davies N, Moreau R, Paradis V, Moore K, Mookerjee R, Jalan R. Liver Int. 2013;33:398-409
Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau R, Jalan R, Sarin SK, Piano S,Moore K, Lee SS, Durand F, Salerno F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. International Club of Ascites. Gut. 2015;64(4):531-7.
Mazza G, Rombouts K, Rennie Hall A, Urbani L, Vinh Luong T, Al-Akkad W, Longato L, Brown D, Maghsoudlou P, Dhillon AP, Fuller B, Davidson B, Moore K, Dhar D, De Coppi P, Malago M, Pinzani M. Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. Sci Rep. 2015 Aug 7;5:13079. doi: 10.1038/srep13079
Hamilton F, Hornby J, Sheringham J, Kerry S, Linke S, Solmi F, Ashton C, Moore K.P, Murray E. DIgital Alcohol Management ON Demand (DIAMOND) feasibility randomised controlled trial of a web-based intervention to reduce alcohol consumption in people with hazardous and harmful use versus a face-to-face intervention: protocol. Pilot and Feasibility Studies 2015